<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170090</url>
  </required_header>
  <id_info>
    <org_study_id>ACTICCA-1</org_study_id>
    <secondary_id>2012-005078-70</secondary_id>
    <secondary_id>ACTRN12615001283561</secondary_id>
    <nct_id>NCT02170090</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer</brief_title>
  <acronym>ACTICCA-1</acronym>
  <official_title>Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australasian Gastro Intestinal Trials Group (AGITG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Hepato &amp; Cholangio Carcinoma Group (DHCG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, two stage, prospective, randomized, controlled phase III trial
      designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
      standard of care (capecitabine) and observation in patients after curative intent resection
      of cholangiocarcinoma and muscle invasive gall bladder carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACTICCA-1 investigator initiated trial is funded by the Deutsche Krebshilfe (grant number
      70110215, 70112047) and supported by medac. With respect to data obtained in the ABC-02
      trial, the combination of cisplatin and gemcitabine for 24 weeks as investigational treatment
      was selected. Based on adjuvant trials in pancreatic cancer (e.g. ESPAC IV) with a comparable
      postoperative recovery time, inclusion of patients within a maximum interval of 16 weeks
      between surgery and start of CTx was chosen. Gemcitabine and cisplatin has a relevantly
      higher cumulative dose of gemcitabine 18 vs. 12 applications and may thus be of increased
      efficacy compared to the gemcitabine/oxaliplatin regimen applied in the PRODIGE 12 trial.

      Based on the data of the BILCAP trial showing an improvement in median overall survival for
      capecitabine compared to observation alone presented at the annual meeting of the American
      Society of Clinical Oncology on June 4th 2017 in Chicago by the British BILCAP trial group,
      capecitabine has evolved as the new standard of care after curative intent resection of
      biliary tract cancer.

      Based on these data the comparative efficacy of gemcitabine/cisplatin and capecitabine needs
      to be established.

      Therefore, the ACTICCA trial will be amended to compare gemcitabine and cisplatin to the
      newly established standard regimen in the adjuvant setting capecitabine, aiming for
      superiority of the combination regimen vs. the oral monotherapy This will be based on the
      BILCAP protocol, applying the similar dosing, assessments and dose modifications as in
      BILCAP, including dose calculation and patient diary.

      As data of recent trials like the French PRODIGE 12/ACCORD 18 trial have clearly shown that
      in terms of efficacy of an adjuvant chemotherapy there is no difference between
      cholangiocarcinoma and gall bladder carcinoma, these two subtypes are pooled and location was
      added as an stratification factor.

      Randomization will be 1:1 with adjuvant CTx for 24 weeks and imaging every 12 weeks in the
      experimental arm and standard of care (capecitabine) and observation in the control arm.

      The primary endpoint is DFS and secondary endpoints include recurrence free survival, OS,
      safety and tolerability of adjuvant CTx, quality of life, and patterns of disease recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Disease free survival rate at 24 months (DFSR@24)</time_frame>
    <description>DFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival rate at 24 months (DFSR@24)</measure>
    <time_frame>24 months</time_frame>
    <description>DSFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>24 months</time_frame>
    <description>RFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>84 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (assessed by the rate of patients with adverse events according to NCI CTC AE v4.03)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>48 months</time_frame>
    <description>QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function of biliodigestive anastomosis (in terms of surgical revision, requirement for PTCD)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and severity of biliary tract infections</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of disease recurrence</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">781</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gall Bladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter)
and Observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily)
and Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2</description>
    <arm_group_label>Gemcitabine plus Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 25mg/m2</description>
    <arm_group_label>Gemcitabine plus Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1250mg/m2</description>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All enrolled patients will postoperatively be assessed for eligibility for the treatment
        phase. Additionally patients not previously enrolled into the trial for whatever reason
        (e.g. incidental finding during surgery) will be evaluated for eligibility.

          -  Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or
             extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after
             radical surgical therapy with macroscopically complete resection (mixed tumor entities
             (HCC/CCA) are excluded)

          -  Macroscopically complete resection (R0/1) within 6 (-16) weeks before scheduled start
             of chemotherapy

          -  ECOG 0-1

          -  Age ≥18 years

          -  Adequate hematologic function

          -  Adequate liver function

          -  Adequate renal function

          -  No active uncontrolled infection, except chronic viral hepatitis under antiviral
             therapy

          -  No concurrent treatment with other experimental drugs or other anti-cancer therapy,
             treatment in a clinical trial within 30 days prior to randomization

          -  Negative serum pregnancy test within 7 days of starting study treatment in
             pre-menopausal women and women &lt;1 year after the onset of menopause (Note: a negative
             test has to be reconfirmed by a urine test, should the 7-day window be exceeded)

        Criteria for initial study enrolment

          -  Written informed consent

          -  No prior chemotherapy for cholangiocarcinoma

          -  No previous malignancy within 3 years or concomitant malignancy, except:
             non-melanomatous skin cancer or adequately treated in situ cervical cancer

          -  No severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction in the last 3 months,
             significant arrhythmia)

          -  Absence of psychiatric disorder precluding understanding of information of trial
             related topics and giving informed consent

          -  No serious underlying medical conditions (judged by the investigator), that could
             impair the ability of the patient to participate in the trial

          -  Fertile women (&lt; 1 year after last menstruation) and procreative men willing and able
             to use effective means of contraception (oral contraceptives, intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly or surgically sterile)

          -  No pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Wege</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Stein</last_name>
    <phone>004940741056882</phone>
    <email>a.stein@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Li</last_name>
    <phone>004940741058572</phone>
    <email>j.li@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bankstown Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Merrett, Prof</last_name>
      <email>neil.merrett@sswahs.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Ray Asghari, Dr</last_name>
      <email>Ray.Asghari@sswahs.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital Cancer Care</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Shannon, Dr</last_name>
      <email>jenny.shannon@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Deme Karikios, Dr</last_name>
      <email>deme.karikios@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winston Liauw, Prof</last_name>
      <email>winston.liauw@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Winston Liauw</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrin Sjoquist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Goldstein, Prof</last_name>
      <email>d.goldstein@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>N N</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Bonaventura, Dr</last_name>
      <email>tony.bonaventura@calvarymater.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Varma, Dr</last_name>
      <email>suresh.varma@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Burge</last_name>
      <email>matthew.burge@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Barnes</last_name>
      <email>david.barnes2@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Warren Joubert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Ladum, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uladimir Andelkovic, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Karapetis</last_name>
      <email>c.karapetis@flinders.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Van Hazel, Dr</last_name>
      <email>Guy.VanHazel@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rudolfstift Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gruenberger, Prof</last_name>
      <email>tgruenberger@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Henrik Jensen, Dr</last_name>
      <email>lars.henrik.Jensen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Luedde, Prof</last_name>
      <email>tluedde@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Marcel Binneboesel, PD</last_name>
      <email>mbinneboesel@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, PD</last_name>
      <phone>030 450 55 3222</phone>
      <email>marianne.sinn@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Uwe Pelzer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Folprecht, Prof</last_name>
      <phone>0351 458 4794</phone>
      <email>gunnar.folprecht@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Conrad Heuchel, Dr</last_name>
      <email>conrad.heuchel@uniklinikum-dresden.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W T Knoefel, Prof</last_name>
      <email>knoefel@uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kasper, Prof</last_name>
      <phone>0049 201 723 2039</phone>
      <email>stefan.kasper@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Virchow, Dr</last_name>
      <email>isabel.virchow@uk-essen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf Bechstein, Prof</last_name>
      <email>wolf.bechstein@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Schnitzbauer, Prof</last_name>
      <email>Andreas.Schnitzbauer@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Heeg, Dr</last_name>
      <email>steffen.heeg@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Moritz Schiemer, Dr</last_name>
      <email>moritz.schiemer@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Stein, PD</last_name>
      <phone>004940741056882</phone>
      <email>a.stein@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Vogel, Prof</last_name>
      <email>vogel.arndt@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Wirth, Dr</last_name>
      <email>Wirth.Thomas@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Springfeld, MD PD</last_name>
      <email>Christoph.Springfeld@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Karl-Heinz Weiss, Prof</last_name>
      <email>Karl-Heinz.Weiss@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Saarland</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Lammert, Prof</last_name>
      <email>frank.lammert@uks.eu</email>
    </contact>
    <contact_backup>
      <last_name>Simone Zimmermann, Dr</last_name>
      <email>simone.zimmermann@uks.eu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Lindig, Dr</last_name>
      <phone>0049 3641 9324586</phone>
      <email>udo.lindig@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Ekkehard Eigendorff, Dr</last_name>
      <email>Ekkehard.Eigendorff@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Becker, Prof</last_name>
      <email>thomas.becker@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Nils Heits, Dr</last_name>
      <email>Nils.Heits@uksh-kiel.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Weinmann, PD</last_name>
      <email>arndt.weinmann@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Marcus-Alexander Woerns, PD</last_name>
      <email>marcus-alexander.woerns@unimedizin-mainz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Schulte, Dr</last_name>
      <email>nadine.schulte@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Sebastian Belle, Dr</last_name>
      <email>sebastian.belle@umm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Munich Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Rentsch, Prof</last_name>
      <email>Markus.Rentsch@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andrej Khandoga, Prof</last_name>
      <email>Andrej.Khandoga@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kilian Weigand, PD</last_name>
      <email>kilian.weigand@ukr.de</email>
    </contact>
    <contact_backup>
      <last_name>Arne Kandulski, PD</last_name>
      <email>arne.kandulski@ukr.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Kreth, Dr</last_name>
      <email>florian.kreth@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Bitzer, Prof</last_name>
      <email>michael.bitzer@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ettrich, Dr</last_name>
      <email>thomas.ettrich@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Angelika Kestler, Dr</last_name>
      <email>angelika.kestler@uniklinik-ulm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Kunzmann, Prof</last_name>
      <email>zapm_haemonk@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Ingo Klein, Prof</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Klümpen</last_name>
      <email>h.klumpen@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Groningen Cancer Center</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.A.P. Hospers, Prof.</last_name>
      <email>g.a.p.hospers@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith de Vos</last_name>
      <email>judith.de.vos@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas Groot Koerkamp, Dr</last_name>
      <email>B.GrootKoerkamp@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Janssen Kiki, Dr</last_name>
      <email>q.janssen@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marjolein Homs, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferry Eskens, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja Haj Mohammad, MD</last_name>
      <email>N.HajMohammad@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hampshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Jackson, Dr</last_name>
      <email>andrew.jackson@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Rees, Dr</last_name>
      <email>charlotte.rees@hhft.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuk Ting Ma, Dr</last_name>
      <email>YukTing.Ma@uhb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Pankaj Punia, Dr</last_name>
      <email>Pankaj.Punia@uhb.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hikish, Dr</last_name>
      <email>Tamas.hikish@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital Cambridge</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pippa Corrie, Dr</last_name>
      <email>pippa.corrie@addenbrookes.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ajithkumar Tharkamma, Dr</last_name>
      <email>tharkamma.ajithkumar@addenbrookes.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Williams, Dr</last_name>
      <email>Hilary.Williams4@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Graham, Dr</last_name>
      <email>janet.graham@glasgow.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Derek Grose, Dr</last_name>
      <email>derek.grose@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David McIntosh, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Wilson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Graham, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derek Grose, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospitals</name>
      <address>
        <city>Great Yarmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Dernedde, Dr</last_name>
      <email>ulrike.dernedde@jpaget.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>May Thu Han, Dr</last_name>
      <email>maythu.han@jpaget.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital Guildford</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Dhillon, Dr</last_name>
      <email>tony.dhillon@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Rathbone, Dr</last_name>
      <email>emma.rathbone@cht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jo Dent, Dr</last_name>
      <email>jo.dent@cht.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Coyle, Dr</last_name>
      <email>christopher.coyle@imperial.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nawa Amin, Dr</last_name>
      <email>Nawa.amin@imperial.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Harpreet Wasan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Coyle, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nawa Amin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roopinder Gillmore, Dr</last_name>
      <email>rgillmore@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Thomas's Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Bridgewater, Prof</last_name>
      <email>j.bridgewater@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Waters, Dr</last_name>
      <email>justin.waters@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hubner, Dr</last_name>
      <email>Richard.Hubner@christie.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mairead McNamara, Dr</last_name>
      <email>Mairead.McNamara@christie.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital Newcastle</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Arora, Dr</last_name>
      <email>arvind.arora@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dhanny Gomez, Dr</last_name>
      <email>dhanny.gomez@nuh.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Cogill, Dr</last_name>
      <email>geoffrey.cogill@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>David Sherriff, Dr</last_name>
      <email>david.sherriff@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital Sheffield</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Darby, Dr</last_name>
      <email>suzanne.darby@sth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Wadsley, Dr</last_name>
      <email>jonathan.wadsley@sth.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Rees, Dr</last_name>
      <email>charlotte.rees@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>John Primrose, Prof</last_name>
      <email>j.n.primrose@soton.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Palmer, Prof</last_name>
      <email>daniel.palmer@liverpool.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Olusoya Faluyi, PhD</last_name>
      <email>olusola.faluyi@clattebridgecc.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.225</url>
    <description>Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Edeline, Bonnetain et al.</description>
  </link>
  <link>
    <url>http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4006</url>
    <description>Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. Primrose, Fox et al.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>muscle invasive gall bladder carcinoma</keyword>
  <keyword>translational research</keyword>
  <keyword>multidisciplinary</keyword>
  <keyword>AIO, DGAV, DGVS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

